Since the end of last year, Orum Therapeutics, Chong Kun Dang Pharmaceutical (CKD Pharm), LegoChem Biosciences, and others have successfully secured large-scale technology transfer agreement with an upfront payment of 100 billion won. Out-licensing contracts with upfront payment scale over 10% of the total contract value have been on the rise due to the high value of technology exports for new drugs.

According to the industry on the 9th, LG Chem signed a technology transfer agreement with Rhythm Pharmaceuticals on the 5th for a rare obesity drug candidate LB54640. Under the agreement, Rhythm Pharmaceuticals will acquire the global development and sales rights of LB54640.

LB54640 is the world